By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Diabetes. According to news reporting originating in Bronx, New York, by NewsRx journalists, research stated, "Obesity is important for the development of type-2 diabetes as a result of obesity-induced insulin resistance accompanied by impaired compensation of insulin secretion from pancreatic beta cells. Here, based on a randomized pilot clinical trial, we report that intranasal oxytocin administration over an 8-week period led to effective reduction of obesity and reversal of related prediabetic changes in patients."
The news reporters obtained a quote from the research from the Albert Einstein College of Medicine, "Using mouse models, we further systematically evaluated whether oxytocin and its analogs yield therapeutic effects against prediabetic or diabetic disorders regardless of obesity. Our results showed that oxytocin and two analogs including [Ser4, Ile8]-oxytocin or [Asu1,6]-oxytocin worked in mice to reverse insulin resistance and glucose intolerance prior to reduction of obesity. In parallel, using streptozotocin-induced diabetic mouse model, we found that treatment with oxytocin or its analogs reduced the magnitude of glucose intolerance through improving insulin secretion. The anti-diabetic effects of oxytocin and its analogs in these animal models can be produced similarly whether central or peripheral administration was used."
According to the news reporters, the research concluded: "Oxytocin and its analogs have multi-level effects in improving weight control, insulin sensitivity and insulin secretion, and bear potentials for being developed as therapeutic peptides for obesity and diabetes."
For more information on this research see: Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. Plos One, 2013;8(5):e61477. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)
Our news correspondents report that additional information may be obtained by contacting H. Zhang, Dept. of Molecular Pharmacology, Diabetes Research Center, Institute of Aging, Albert Einstein College of Medicine, Bronx, New York, United States (see also Diabetes).
Keywords for this news article include: Bronx, Obesity, New York, Diabetes, Treatment, Bariatrics, Proinsulin, United States, Overnutrition, Peptide Hormones, Diet and Nutrition, Nutrition Disorders, North and Central America, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .